When and how should atomoxetine (Strattera) be combined with bupropion (Wellbutrin) in a patient with attention‑deficit/hyperactivity disorder and depressive symptoms refractory to monotherapy, including recommended dosing, titration, contraindications, and monitoring?

Combining Strattera and Wellbutrin for ADHD with Comorbid Depression

The combination of atomoxetine (Strattera) and bupropion (Wellbutrin) can be used in patients with ADHD and depressive symptoms refractory to monotherapy, but proceed with extreme caution due to a significant pharmacokinetic interaction that increases atomoxetine exposure 5-fold.

Critical Drug Interaction Warning

Bupropion inhibits CYP2D6, causing atomoxetine plasma levels to increase approximately 5-fold (AUC increased from 1580 to 8060 ng*h/mL) while decreasing the active metabolite 4-hydroxyatomoxetine-O-glucuronide by 1.5-fold 1. This transforms extensive metabolizers into functional poor metabolizers, dramatically altering atomoxetine's safety profile.

When to Consider This Combination

Clinical Scenarios:

• Primary indication: ADHD with comorbid depression where monotherapy with either agent has failed to adequately control both conditions
• Treatment-resistant ADHD: Patients who have not responded adequately to stimulant monotherapy or atomoxetine alone
• Contraindications to stimulants: Patients with substance use history, cardiovascular concerns, or tic disorders where stimulants are problematic

Important Context from Guidelines:

The 2002 AACAP guidelines note that "no data support a single antidepressant to treat both ADHD and MDD" and that "bupropion and tricyclics are second-line agents, at best, for treating ADHD" 2. However, these guidelines predate atomoxetine's widespread use and the specific interaction data.

Dosing and Titration Protocol

Starting the Combination:

If starting atomoxetine in a patient already on bupropion:

• Start atomoxetine at poor metabolizer dosing: 0.5 mg/kg/day (approximately 40 mg/day for adults)
• Maximum dose should not exceed 80 mg/day (versus the typical 100 mg/day maximum)
• Titrate slowly over 4-6 weeks, monitoring closely for adverse effects
• The FDA label specifies that atomoxetine dosing in poor metabolizers should be 0.5 mg/kg/day initially, increased to 1.2 mg/kg/day only if symptoms don't improve after 4 weeks and the initial dose is well-tolerated 3

If adding bupropion to established atomoxetine therapy:

• Reduce atomoxetine dose by 50% when initiating bupropion to account for the anticipated 5-fold increase in exposure
• Start bupropion at standard dosing (150 mg/day SR or XL, titrating to 300 mg/day as needed for depression)
• Monitor for 2-3 weeks before considering any atomoxetine dose adjustments

Maintenance Dosing:

• Atomoxetine: 40-80 mg/day (total daily dose)
• Bupropion: 150-300 mg/day (SR or XL formulation)
• Can administer atomoxetine once daily in morning or split into morning/evening doses to minimize side effects 4

Contraindications

Absolute Contraindications:

• Narrow-angle glaucoma (atomoxetine contraindication per FDA label) 3
• MAO inhibitor use within 14 days (both medications)
• Seizure disorder or conditions increasing seizure risk (bupropion contraindication)
• Bulimia or anorexia nervosa (bupropion contraindication)
• Abrupt discontinuation of alcohol or benzodiazepines (bupropion)

Relative Contraindications Requiring Careful Assessment:

• Cardiovascular disease (both medications can increase heart rate and blood pressure)
• Severe hepatic impairment
• History of psychosis or bipolar disorder (both can precipitate manic episodes)
• Pregnancy (both Category C; atomoxetine has limited safety data) 5

Monitoring Requirements

Initial Phase (First 4-8 Weeks):

• Weekly assessment for suicidal ideation, particularly in children/adolescents (FDA black box warning for atomoxetine) 3
• Blood pressure and heart rate at baseline, 2 weeks, 4 weeks, then monthly
• ADHD symptom rating scales (e.g., ADHD-RS) at baseline and every 2-4 weeks
• Depression rating scales (e.g., PHQ-9) at baseline and every 2-4 weeks
• Assess for activation, agitation, insomnia, or anxiety

Ongoing Monitoring:

• Monthly visits for first 3-4 months, then every 3 months once stable 2
• Blood pressure and heart rate at each visit
• Weight monitoring (atomoxetine can decrease appetite)
• Liver function tests if clinical signs of hepatotoxicity develop (jaundice, dark urine, right upper quadrant tenderness)
• Reassess need for combination therapy every 6-12 months

Specific Adverse Effects to Monitor:

Atomoxetine-related (amplified by interaction):

• Decreased appetite, nausea, vomiting (most common)
• Sedation or fatigue
• Urinary hesitation or retention
• Sexual dysfunction
• Severe liver injury (rare but serious) 3

Bupropion-related:

• Insomnia, agitation, anxiety
• Dry mouth
• Seizures (dose-dependent risk)
• Hypertension

Clinical Efficacy Evidence

Recent systematic reviews show mixed evidence for combination therapy:

• One 2025 review found no significant difference in ADHD severity reduction between atomoxetine monotherapy and combination therapy overall 6
• However, two studies showed significantly decreased ADHD severity in treatment-resistant patients after switching to combined methylphenidate and atomoxetine 6
• Three studies reported significantly greater adherence with combined therapy versus monotherapy 6

For ADHD with substance use disorders, atomoxetine is recommended to improve ADHD symptoms (weak recommendation), and appears safe in patients with any SUD (strong recommendation) 7. Bupropion has established efficacy for smoking cessation and may provide synergistic benefits 8.

Common Pitfalls to Avoid

1. Failing to adjust atomoxetine dosing for the CYP2D6 inhibition: This is the most critical error and can lead to severe adverse effects
2. Inadequate monitoring for suicidality in young patients: The FDA black box warning exists for atomoxetine in children/adolescents 3
3. Using this combination as first-line therapy: Guidelines recommend stimulants as first-line for ADHD 4, 9
4. Ignoring cardiovascular risk factors: Both medications affect blood pressure and heart rate
5. Abrupt discontinuation: Atomoxetine should be tapered; bupropion discontinuation can cause withdrawal symptoms

Alternative Approaches

Before resorting to this combination, consider:

• Optimized stimulant monotherapy (methylphenidate or amphetamines remain first-line) 4, 9
• Stimulant plus SSRI for comorbid depression (better evidence base) 10
• Atomoxetine monotherapy at adequate doses (1.2-1.8 mg/kg/day in extensive metabolizers) 3
• Cognitive behavioral therapy plus medication (combination CBT + SSRI shows moderate evidence for anxiety/depression) 10
• Alpha-2 agonists (guanfacine or clonidine) as adjuncts, particularly if tics or sleep issues present 4, 2